ClinicalTrials.gg
CompletedNCT01216943Updated Sep 19, 2013Results posted

Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension

A Phase 3 interventional study of bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-19.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Glaucoma by AbbVie — none open to participants now, none under way, none of them phase 3. Glaucoma · AbbVie.

Enrollment
20th of 31
126 · median 158
Started
2010
with 3 others
Phase 3
13 of 34
none open now
Registered
18th of 34
by date

Among the 34 studies in Glaucoma by AbbVie, this one is the 20th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2010, is one of 13 in phase 3, and was the 18th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 34 studies in Glaucoma by AbbVie is open now. The open studies under Glaucoma, anywhere →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies in Glaucoma by AbbVie as a file.
02

Study summary

This study will investigate the safety and efficacy of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) in patients with glaucoma or ocular hypertension who have elevated intraocular pressure (IOP) on brimonidine/timolol ophthalmic solution.

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Glaucoma and/or ocular hypertension in both eyes
  • Requires IOP-lowering treatment in both eyes

Exclusion criteria

Exclusion Criteria:

  • Other active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)
  • Current or anticipated use of ocular medications other than study medications, except for intermittent use of artificial tears
  • Use of oral, injectable or topical within 21 days
  • Iridectomy or laser peripheral iridotomy in the study eye within 3 months
  • Uncomplicated cataract surgery in the study eye within 6 months
  • Incisional glaucoma surgery in the study eye within 12 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Triple Combination Therapy

    One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.

    Drug: bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution

Interventions

  • Drugbimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution

    One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye

    IOP is a measurement of the fluid pressure inside the eye. Mean diurnal IOP is the mean of the IOP values at hour 0, hour 2 and hour 8 at each visit in the study eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).

    Time frame: Baseline, Week 12

07

Results

Posted Sep 19, 2013

Participant flow

Participant flow — Overall Study
MilestoneTriple Combination Therapy
Started126
Completed113
Not completed13

Outcome measures

PrimaryChange From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye

IOP is a measurement of the fluid pressure inside the eye. Mean diurnal IOP is the mean of the IOP values at hour 0, hour 2 and hour 8 at each visit in the study eye. A negative number change from baseline indicates a reduction in IOP (improvement), and a positive number change from baseline indicates an increase in IOP (worsening).

Time frame:
Baseline, Week 12
Reported as:
Mean · Millimeters of Mercury (mmHg)
Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) in the Study Eye
Millimeters of Mercury (mmHg)Triple Combination Therapy
Baseline22.35 ± 3.417
Change from Baseline at Week 12-3.98 ± 2.856

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triple Combination Therapy—0/121 (0%)20/121 (16.5%)
Most frequent other events
Most frequent other events
EventTriple Combination Therapy
Conjunctival HyperaemiaEye disorders20/121

Baseline characteristics

Age, Customized
Age, Customized(Participants)Triple Combination Therapy
<45 years11
45 to 65 years84
>65 years31
Sex: Female, Male
Sex: Female, Male(Participants)Triple Combination Therapy
Female48
Male78
08

Study locations

1 site
  • Coimbatore, Tamil Nadu, India
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2010, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2010
First posted
Oct 7, 2010
Start
Nov 2010
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Sep 19, 2013
Last update
Sep 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01216943
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 7, 2010
Start date
Nov 2010
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Sep 19, 2013
Last update
Sep 19, 2013

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion